Back to Trades
Total Value
$636.0K
Filing Date
Nov 20, 2026
1 transactions
Trade Summary
On Nov 20, 2026, DUGGAN ROBERT W, Co-Chief Executive Officer, Director, 10% Owner, reported $636.0K of Summit Therapeutics Inc. (SMMT) across 1 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Reported prices ranged from $1.06. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Summit Therapeutics Inc.
- Ticker Symbol
- SMMT
- CIK
- 0001599298
Insider Information
- Name
- DUGGAN ROBERT W
- Role
- Co-Chief Executive Officer, Director, 10% Owner
- Location
- MIAMI, FL
Filing Details
- Filing Date
- Nov 20, 2026
- Transaction Date
- Nov 20, 2026
- Accession Number
- 0001055919-26-000012
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Nov 20, 2026 | Common Stock | 300,000 | $1.06 | Exercise | $318.0K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Nov 20, 2026 | Stock Option (right to buy) | 300,000 | $1.06 | Exercise | $318.0K |
Want live alerts when DUGGAN ROBERT W trades again?
Download Insider Trades to track SMMT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)On November 20, 2026, the Spouse of Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
- (F2)The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- (F3)The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.